WEBULL

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Simply Wall St · 3d ago
  • In July 2026, Telix Pharmaceuticals reported positive early-stage data for its PSMA-targeting therapy TLX591-Tx in advanced prostate cancer, initiated Phase 3 development of TLX250-Tx for clear cell renal cell carcinoma, raised its Fiscal Year 2026 revenue and other income outlook to more than US$1 billion, and entered a collaboration with Regeneron that included an initial US$40 million payment.
  • These updates indicate Telix is moving multiple radiopharmaceutical therapies into later-stage trials while leveraging its imaging assets like Illuccix and TLX250-Px to support a theranostic business model.
  • We’ll now consider how Telix’s raised revenue guidance above US$1 billion reshapes its existing investment narrative and forward-looking risk balance.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Telix Pharmaceuticals Investment Narrative Recap

To own Telix today, you need to believe in radiopharmaceuticals moving from niche to mainstream, with Telix’s theranostic model turning imaging success into meaningful therapy revenue. The key near term catalyst remains clinical and regulatory progress for TLX591-Tx in metastatic prostate cancer, while the biggest risk is that an increasingly crowded PSMA imaging market and ongoing SEC scrutiny keep margins and sentiment under pressure. The latest guidance upgrade above US$1 billion revenue does not remove these execution and regulatory risks.

Among the recent updates, the publication of ProstACT SELECT data for TLX591-Tx stands out. It reinforces the link between Illuccix imaging and Telix’s lead prostate therapy now in Phase 3, which sits at the heart of the company’s theranostic story. For investors, that tighter imaging therapy connection is important because it underpins Telix’s attempt to move beyond Illuccix driven revenue toward higher value therapeutic income if pivotal trials read out well.

Yet even with upgraded FY2026 revenue guidance, you should be aware that execution setbacks in key trials like ProstACT GLOBAL could still...

Read the full narrative on Telix Pharmaceuticals (it's free!)

Telix Pharmaceuticals' narrative projects $1.2 billion revenue and $81.9 million earnings by 2029. This requires 15.8% yearly revenue growth and an $89.0 million earnings increase from -$7.1 million today.

Uncover how Telix Pharmaceuticals' forecasts yield a A$23.36 fair value, a 59% upside to its current price.

Exploring Other Perspectives

ASX:TLX 1-Year Stock Price Chart
ASX:TLX 1-Year Stock Price Chart

Before this news, the most cautious analysts were assuming roughly US$1.2 billion revenue by 2029 and still worried that long, complex pivotal trials might delay commercialization and keep Telix loss making longer than you expect.

Explore 16 other fair value estimates on Telix Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Telix Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free Telix Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Telix Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.